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Abstract Relapses are a characteristic clinical feature of
multiple sclerosis (MS), but an appreciation of factors that
cause them remains elusive. In this study, we have exam-
ined seasonal variation of relapse in a large population-
based MS cohort and correlated observed patterns with age,
sex, disease course, and climatic factors. Relapse data were
recorded prospectively in 2076 patients between 2005 and
2014. 3902 events were recorded in 1158 patients (range
0–24). There was significant seasonal variation in relapse
rates (p\ 0.0001) and this was associated with monthly
hours of sunshine (odds ratio OR 1.08, p = 0.02). Relapse
rates were highest in patients under the age of 30 (OR 1.42,
p = 0.0005) and decreased with age. There was no evi-
dence of different relapse rates for males compared to
females (OR 0.90, p = 0.19). Identification of potentially
modifiable environmental factors associated with temporal
variation in relapse rates may allow alteration of risk on a
population basis and alteration of outcome of established
disease once established. Future epidemiological studies
should examine dynamic environmental factors with serial
prospective measurements and biological sampling. Sig-
nificant seasonal differences in relapse rates highlight the
importance of environmental factors in disease expression
and should be taken into account when planning clinical
trials in which relapse frequency is an outcome. In addi-
tion, identification of potentially modifiable factors asso-
ciated with this variation may offer unique opportunities
for alteration of risk of relapse and long-term outcome on a
population level, and suggest putative biological mecha-
nisms for relapse initiation.
Keywords Multiple sclerosis  Epidemiology  Relapses 
Seasonal
Introduction
Relapses are a key feature of multiple sclerosis (MS); most
patients will experience at least one relapse over the course
of their disease, and the majority of currently available
disease modifying therapies (DMTs) are targeted at reducing
their frequency. A relapse is the clinical manifestation of
acute inflammation and focal demyelination in a clinically
eloquent region of the central nervous system (CNS), lead-
ing to a discrete episode of neurological dysfunction which
may recover fully or partially [4]. However, identification of
triggers that instigate the inflammatory cascade, and subse-
quent demyelination and gliosis, remains elusive.
A seasonal variation in relapses has been demonstrated in
some [2, 7, 9, 23, 24, 26, 29, 31] but not all [8, 17, 18, 22]
previous studies. However, many of these are powered to
detect only the largest deflections from a random relapse
distribution, whilst in larger pooled studies, up to 38% of
relapses have been excluded as the date of relapse was
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unknown, leading to difficulties in interpretation of results
[26]. Where seasonal variation has been identified, peak
frequencies in spring and summer months irrespective of
latitude have generally been observed [2, 7, 9, 17, 23], and
this pattern has also been supported by magnetic resonance
imaging data [16]. Direct comparison or meta-analysis of
these studies, which would allow detailed interrogation of
available data and population sub-groups, is prevented by
variation in methodology and geographical location. Clari-
fication of seasonal relapse patterns would provide direction
for future research into environmental factors relevant to MS
and may suggest putative mechanisms for relapse initiation.
To date, there have been no large-scale studies of sea-
sonal relapse variation in northern Europe, an area which has
the highest prevalence of MS in the world. In this study, we
have collected relapse data on a large population-based
cohort of patients within south east Wales over 10 years to
examine seasonal variation in relapse frequency, and have
compared observed patterns with selected climatic variables.
Methods
Patient recruitment
The neuroinflammatory unit at the University Hospital of
Wales serves the population of Cardiff and Vale and Cwm
Taf Health Boards, comprising the city of Cardiff and the
surrounding rural and ex-mining areas of the Vale of
Glamorgan and the Rhondda valley, while the city of
Newport and its surroundings including Monmouthshire
are served by clinics based at the Royal Gwent Hospital. A
cross-sectional epidemiological study establishing the
region as a high prevalence area for MS was first per-
formed in 1985 [28], and has periodically been updated
over subsequent years [10]. Since 1999, prospective lon-
gitudinal clinical data have been collected on all patients
referred to the regional neuroinflammatory services. At first
presentation, information is collected on demographics,
details of onset of disease, current Expanded Disability
Status Scale (EDSS) [13] score, current disease course, and
relapses. Patients are reviewed routinely every
6–12 months, when further data are collected on current
disease course, EDSS score, medication and its effects, and
whether the patient has had a relapse since the last review.
In addition, there is a weekly rapid access clinic which
patients can directly access for assessment and treatment of
new neurological symptoms including relapses. Relapses
are defined as acute or subacute deteriorations in neuro-
logical function in the absence of fever or infection, with
partial or full recovery [15].
All patients provided written informed consent. The
study was approved by the South East Wales Research
Ethics Committee (ref 05/WSE03/111). All patients were
included in this study, unless the date of their most recent
review was before 1st January 2005, or if onset of disease
was after 31st December 2014.
Climate data
Average data for south east Wales on minimum tempera-
ture, maximum temperature, hours of sunshine, and mil-
limeters of rainfall for each month between January 2005
and December 2014 were downloaded from the Met Office
website (http://www.metoffice.gov.uk/public/weather/cli
mate-historic/tab=climateHistoric, accessed 29th February
2016). UV index data for the UK between January 2005
and December 2014 were downloaded from the Depart-
ment for Environment, Food and Rural Affairs (DEFRA)
(http://ozone-uv.defra.gov.uk/uv/data_search.php, accessed
29th February 2016).
Statistical analysis
Patients contributed to each month of the study between
onset of first MS symptoms and the most recent date of
review by neuroinflammatory services. Where onset was
before 1st of January 2005, patients contributed from that
date, but if onset was after 1st January 2005, they con-
tributed from the date of onset of symptoms. If patients
were reviewed after 31st December 2014, they contributed
to all months up to this date, but if the date of last
encounter was earlier than 31st December 2014, data were
censored at the time of the last encounter. For example, a
patient with onset of disease in February 2006 who is still
under review and was last seen in August 2016 would
contribute to all months of the study between February
2006 and December 2014. A patient with onset in March
1990 who died in November 2010 would contribute to all
months of the study between January 2005 and November
2010.
Initially, relapse counts were analysed by month using a
Poisson regression model. The median number of relapses
per month was used as the reference. Following this,
logistic regression, clustered by patient, was used to anal-
yse contribution of climate variables (hours of sunshine,
rainfall, minimum and maximum monthly temperature, and
UV index) to odds of relapse in any given month. Any
relapse where the date was unknown was excluded from
analysis. Current age, sex, and current disease course (re-
lapsing–remitting or progressive) were included as co-
variates. Our data set consists of observations for each
month, for all patients who were present in the study during
that month. A logistic regression model is used, because for
each patient and for each month, they have a ‘‘1’’ if they
had a relapse in that month, and a ‘‘0’’ otherwise. In view
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of previous studies suggesting a lagged effect of UV index
[29], models were generated using raw data and also 1 and
2 month lags for climate variables. The Akaike Informa-
tion Criterion (AIC) was used to select the best-fitting
model.
Association between climate and recovery from relapse
was also tested using clustered logistic regression. Relapses
were classified according to whether the patient returned to
the same level of disability recorded prior to relapse, or not.
Only patients with relapsing disease were included in this
model, to avoid the potential confounding effect of back-
ground progressive disease on recovery from relapses.
To analyse whether season of onset was associated with
longer term outcomes, onset events were grouped into
seasons: December, January, and February classified as
winter; March, April, and May as spring; June, July, and
August as summer; and September, October, and Novem-
ber as autumn. Kaplan–Meier survival analysis and Cox
proportional hazards regression were used to analyse the
relationship between season of onset of MS and time to
EDSS 3.0 and 4.0.
R v3.2.2 was used for all analyses [20].
Results
Patients
2076 patients were included in this study, of whom 1450
(69.4%) were female. On the 1st of January 2005, 374
patients were aged less than 30, 528 were between 30 and
39, 534 were between 40 and 49, and 640 were 50 or older.
Disease course at onset was relapsing in 1790 patients
(86%) and progressive in 238 (11.5%). Of relapsing onset
patients, 926 (52%) subsequently converted to SPMS.
Mean duration of patient follow-up in the study was
7.8 years.
1158 patients (55.8%) experienced one or more relapses;
the remaining 918 (44.2%) had no relapses during the
study. 301 patients had one, 246 had two, 174 had three,
and 437 had more than three relapses. Median number of
relapses was 1 (interquartile range 0–3). Mean annualised
relapse rate (ARR) for the cohort was 0.34 and 0.61 for
those who had at least one relapse during the study period
(Table 1).
Relapses
Over the 10 year study period, there were 3902 events in
1158 patients. 528 (13.5%) were first events, and the
remainder were subsequent relapses. The date for 234
(6.0%) of the events was unknown and could not be
determined even after review of the medical notes. These
events were not included in the statistical analysis. 937
relapses (24.0%) occurred in male patients, and 1292
(33.1%) in patients with progressive disease.
There was a sinusoidal pattern of number of events per
month, with a peak in June (373 events, rate ratio 1.22,
95% confidence interval CI 1.05–1.42, p = 0.01), and a
trough in August (256 events, rate ratio 0.84, 95%
Table 1 Patient characteristics
All patients Patients with events Patients without events
Total number 2076 1158 918
Female (%) 1450 (69.8) 851 (73.5) 599 (65.3)
Current disease course:
RRMS (%) 864 (41.6) 711 (61.4) 153 (16.7)
SPMS (%) 926 (44.6) 355 (30.7) 571 (62.2)
PPMS (%) 238 (11.5) 92 (7.9) 146 (15.9)
Mean study follow-up (SD) 7.2 years (4.7) 6.8 years (4.5) 7.8 years (4.9)
Mean age at onset (SD) 32.8 years (11.0) 32.6 years (10.8) 33.0 years (11.2)
Mean current age (SD) 54.2 years (13.8) 47.5 years (11.6) 62.6 years (11.6)
Mean disease duration (SD) 18.8 years (12.0) 13.5 years (9.1) 26.6 years (11.6)
RRMS relapsing–remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, SD
standard deviation
Fig. 1 Line graph showing rate ratios and confidence intervals for
MS events in each month, as calculated using Poisson regression
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confidence interval 0.71–0.99, p = 0.04) (Fig. 1). The
median number of events in any calendar month was 305.
A summary of relapse numbers by month and corre-
sponding climate variables for south east Wales are pro-
vided in Table 2.
Clinical variables and relapses
A relapse was more likely to occur in relapsing than pro-
gressive MS (odds ratio [OR] 1.32, 95% CI 1.12–1.54,
p = 0.0005). MS event frequency decreased with age
(30–39: reference; under 30: OR 1.42, 95% CI 1.16–1.73;
40–49: OR 0.64, 95% CI 0.53–0.76; 50 and over: OR 0.27,
95% CI 0.22–0.33, p\ 0.0001). There was no difference
in pattern of relapses between men and women (male: OR
0.90, 95% CI 0.77–1.05, p = 0.19), and a similar age-re-
lated seasonal pattern was seen in both sexes (Fig. 2).
There was no interaction between age group and sex
(p = 0.61).
Climate variables and seasonal relapse pattern
The seasonal variation in relapses was confirmed in the
logistic regression model (p\ 0.001). The best-fitting
model included hours of sunshine (OR 1.08, 95% CI
1.01–1.16, p = 0.023), age group (under 30: OR 1.42, 95%
CI 1.16–1.73; 30–39: reference; 40–49: OR 0.64, 95% CI
0.53–0.76; 50 or older: OR 0.27, 95% CI 0.22–0.33,
p\ 0.0001), and disease course (progressive disease: OR
0.76, 95% CI 0.65–0.89, p = 0.00059) (Table 3). There
was no association between relapses and sex (OR 0.90,
95% CI 0.77–1.05, p = 0.19). Models including other
climate variables (rainfall, maximum or minimum
temperature, or UV levels) had a less good fit as measured
by AIC than the model including sunshine. The final model
including hours of sunshine did not account for all the
variance in relapse pattern observed.
Climate variables and recovery from relapse
2729 relapses (70% of the total) were included in this
analysis. Full recovery to the previous level of disability
was observed in 1744, and 985 were followed by an
increased level of disability compared to before relapse.
Seasonal pattern was similar for both groups of relapse
(Fig. 3). There was no association of recovery from a
relapse with any climate variable (data not shown).
Season of onset and time to EDSS milestones
There was a mean of 37 onset events in each month.
Median time to EDSS 3.0 was 3.9 years, and to EDSS 4.0
was 5.7 years. There was no difference in time to EDSS 3.0
or 4.0 by season of onset. This remained the case after
adjustment for age at onset, sex, and disease course in a
Cox proportional hazards regression model (Table 4).
Discussion
In this northern European population-based study spanning
a decade, we have shown a seasonal pattern in MS events,
with a peak in late spring/early summer, and a trough in
late summer. This pattern is most apparent in younger
patients with relapsing–remitting disease and is associated
with monthly hours of sunshine. However, this does not
Table 2 Monthly summary of relapses and climate variables, 2005–2014
Month Relapses Patient-months
observed
Onset
events
Mean max temp
(C)
Mean min temp
(C)
Mean rainfall
(mm)
Mean hours of
sunshine
Mean UV
index
Jan 271 8645 32 8.3 2.4 102.4 57.0 0.23
Feb 321 10182 42 8.5 2.3 63.4 71.8 0.39
Mar 295 7323 35 11.1 3.2 62.6 126.9 0.77
Apr 334 7941 48 14.8 5.5 53.4 171.6 1.25
May 318 8156 45 17.3 8.3 80.2 196.9 1.6
Jun 373 9662 41 20.3 11.1 71.5 204.6 1.78
Jul 286 7184 37 22.2 13.0 87.6 217.1 1.85
Aug 256 6274 29 20.9 12.4 84.5 172.9 1.54
Sep 273 6736 31 19.4 10.8 66.5 138.3 1.24
Oct 304 5778 35 15.7 8.6 103.3 100.6 0.65
Nov 306 5628 37 11.2 4.6 107.6 67.8 0.31
Dec 331 8464 32 8.3 1.8 101.6 49.9 0.19
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Fig. 2 Line graph showing
relapses per month, grouped by
sex (top), age at relapse
(middle), and disease course
(bottom)
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account for all variation observed, suggesting that seasonal
patterns of MS events are multifactorial.
A seasonal pattern in MS relapses has previously been
noted, with most studies reporting a solitary peak in spring
and/or summer months in both northern [2, 17, 23, 26, 31]
and southern hemispheres [7, 26], a pattern which has also
been borne out by meta-analysis [11]. Fewer studies have
detected a nadir in relapse rates, but in studies that have been
able to detect this, the nadir tends to occur in late summer or
autumn [9, 23, 26, 29, 31]. Three studies have not detected
any seasonal variation [8, 18, 22]; however, one of these
studies was a retrospective review of MS hospital admissions
and thus may have overlooked less severe relapses [18], and
the other two were relatively small studies in southern Eur-
ope where seasonal variation in climate may be less than in
northern Europe or America [8, 22]. Indeed, a recent large
study incorporating international data from the MS Base
Registry suggests an effect of latitude on seasonal pattern of
MS events [26]. These findings are also supported by our
study, which is the largest single centre study of its kind and
uses high-quality clinical data collected prospectively in a
well-described cohort, suggesting that a seasonal pattern is
genuine and not due to reporting bias.
There is also objective paraclinical evidence to support
seasonal variation in neuroinflammatory activity; in a
prospective North American study of 44 patients with
parallel sequential MR imaging, new T2 activity was 2–3
times more frequent between March and August, although
no similar increase in clinical events was observed [16].
Alterations in the pattern of seasonal cytokine variation
have also been observed in MS patients: seasonal variation
is seen in healthy controls in IL-4, IL-10, TNF-a, and IFN-
Table 3 Final model for seasonal and clinical factors associated with
relapse in patients with MS
Variable Odds ratio (95% confidence interval) p value
Sunshine 1.08 (1.01–1.16) 0.023
Age group
\30 years 1.42 (1.16–1.73) \0.0001
30–40 years Reference
40–50 years 0.64 (0.53–0.76)
Over 50 years 0.27 (0.22–0.33)
Sex (male) 0.90 (0.76–1.06) 0.19
Disease course
RRMS Reference 0.00059
Progressive 0.76 (0.65–0.89)
Fig. 3 Line graph showing relapses per month observed, by recovery
from the relapse
Table 4 Season of onset and
EDSS milestones
EDSS 3.0 EDSS 4.0
Median time to milestone
Onset in autumn
3.0 (2.1–4.1) 4.5 (3.3–7.8)
Onset in spring
3.9 (3.0–5.7) 5.7 (4.9–7.6)
Onset in summer
3.6 (2.5–4.8) 5.7 (4.2–7.5)
Onset in winter
3.9 (3.2–4.8) 6.2 (4.8–7.6)
Variable Hazard ratio p Hazard ratio p
Cox proportional hazard regression
Onset in autumn Reference Reference
Onset in spring 0.9 (0.6–1.2) 0.37 1.0 (0.7–1.4) 0.55
Onset in summer 0.9 (0.6–1.2) 0.9 (0.6–1.3)
Onset in winter 0.9 (0.7–1.3) 0.9 (0.6–1.3)
Age at onset 1.01 (1.00–1.03) 0.016 1.01 (0.99–1.03) 0.07
Male 1.3 (0.99–1.7) 0.06 1.3 (0.9–1.7) 0.14
Primary progressive 1.9 (1.3–2.8) 0.0007 3.0 (2.0–4.5) \0.0001
1064 J Neurol (2017) 264:1059–1067
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c, but in untreated MS patients, only seasonal variation in
IL-10 was preserved, while in treated MS patients, the
seasonal variation was lost for all four cytokines [27].
Since our study was based on prospectively collected
data from individual patients, we have been able to assess
risk of relapse at an individual level. This is a novel
approach, which has allowed a more detailed analysis of
monthly risk of an event than has previously been possible
and has also allowed us to take into account the contribu-
tion of clinical variables to the probability of a relapse.
An association between UV levels and pattern of MS
events has previously been observed [26, 29], and it has
been proposed that this association occurs as a result of the
mechanism of vitamin D production [29]. The best-fitting
model in our study included hours of sunshine, although
the mechanism by which this might take effect is not clear.
We observed highest odds of relapse during early summer
when hours of sunshine were high, and lowest odds of
relapses during late summer. This implies that if vitamin D
has a role, it cannot be the only factor that is relevant in
triggering a relapse and may be modified by alternative
environmental factors which modulate its effects.
Other factors associated with increased probability of
relapse include younger age [30], shorter disease duration
[30], and viral infections [1, 6], while pregnancy and
breastfeeding [5, 14], serum vitamin D levels [25], and
DMTs [3, 12, 19, 21] appear protective. It seems most
likely that interaction between a number of these and other
factors leads to initiation of CNS inflammation, manifest-
ing clinically as a relapse. However, the relative contri-
bution of individual factors and their contribution to the
pathological sequence of events remain elusive. In addi-
tion, while some factors associated with probability of an
MS event exhibit a seasonal pattern, such as climate vari-
ables or infections, others have a very different risk profile,
such as the declining risk of relapse with increasing age
[30], or the reduction in risk during pregnancy with a return
to the previous levels of risk post-natally [5]. Therefore, it
would seem unlikely that MS events would conform to a
single pattern such as seasonal variation.
This study has a number of strengths. It is a large,
population-based study, with good relapse ascertainment in
a patient cohort that has had detailed clinical follow-up for
more than 10 years. By confining the study to one geo-
graphical area, possible confounding effects of other
environmental factors have been minimised. The analysis
utilised objectively measured climate variables, and
allowed clustering of multiple relapses within a given
individual to be taken into account, thus allowing for
individual variation in relapse rate.
The relapse rate in this study is considerably lower than
that observed in most randomised controlled trials, which
tend to select patients with active or highly active relapsing
disease. This difference in relapse rate may also occur as
the result of a more rigorous surveillance system. However,
our data are comparable with rates seen in prospective
population-based studies and we feel likely to be a true
representation of overall relapse frequency in this cohort.
We also recognise additional limitation in the analysis of
these data; both seasonal variation and age-specific dif-
ferences in relapse frequency may have occurred as a result
of a systematic reporting bias. Although this is difficult to
confidently exclude, it would seem unlikely given the
rigorous methodology and results of previous studies.
In addition, relapses in this study have been grouped by
month, and some excluded by necessity, because no
accurate date could be ascribed. Patients with relapse of
uncertain date appear to be more likely to have primary
progressive disease, have shorter duration of follow-up, be
older, and be male. However, this missing data should only
bias conclusions if the relapses of uncertain date had a
different seasonal pattern than those with a confirmed date.
Only a limited number of climate variables were included
here, and there may be other factors (or combinations of
factors) which could explain remaining monthly variation
in relapse rates. Our model also only adjusts for monthly
(rather than daily) weather, and thus, some residual con-
founding effects could remain. It also adjusts for weather at
the area level (with data on sunshine, rainfall, and tem-
perature from south Wales, but UV index data for the UK
as a whole) so may not represent geographical location on
an individual level. Furthermore, there is no information on
the amount of time each individual spent outside in a given
month, and thus, individual exposure to climate variables is
proxied by the monthly values of these variables, leading to
measurement error in individual exposure.
Finally, the geographical limitations of this study, whilst
minimising confounding by other, unmeasured environ-
mental factors also minimise variation in exposure in this
population. Stronger associations with climate variables
might be observed in a population with a more diverse range
of exposure, both by geography and across the year. All the
climate variables except rainfall were very highly correlated,
and thus, the independent associations of relapse rate with
all climate variables could not be examined.
In conclusion, we have interrogated patterns of relapse
in a large population-based cohort of patients from south
east Wales with detailed clinical data, confirming the
presence of a seasonal pattern in MS events and demon-
strating association with hours of sunshine. However, in
exploring the relative contribution of this and other factors
to observed seasonal variation, we have recognised that the
causes of a relapse are likely to be multifactorial and that a
better understanding of the effect of environmental factors
on the development of MS and its clinical manifestations
remains to be established. This, in turn, may offer
J Neurol (2017) 264:1059–1067 1065
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opportunities for improved treatments, strategies for
relapse prevention, and alteration of risk of disease on a
population level.
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